Lumida
/NKTR
⌘K
Nektar Therapeutics

Nektar Therapeutics

NKTR
$69.76USD-1.26%-0.89 today

MARKET CAP

2.4B

P/E (TTM)

FWD P/E

DAY RANGE

$68 – $71

52W RANGE

$33
$109

AI Summary

Stalk
StalkMedium

NKTR remains in a healthy Stage 2 uptrend above its 200‐day SMA with higher highs and lows, currently experiencing a volume‐light pullback into rising EMAs and the 50 SMA. Short‐term exhaustion and neutral RSI suggest patience, while the medium‐term bias stays bullish. Preferred engagement is on pullback acceptance around $70–72 or upon a sustained reclaim of the 9/20 EMAs.

  • Phase 2b REZOLVE-AD results indicate strong rezpegaldesleukin efficacy in moderate-to-severe atopic dermatitis.
  • A $1B cash and securities balance funds R&D and phase 3 trials through 2027.
  • Shares outstanding jumped from 14.1m to 33.1m, raising significant dilution concerns.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$101.9M$92.1M$90.1M$98.4M$55.2M
YoY %-33.4%-9.7%-2.1%+9.2%-43.9%
P / Sales24.3x4.5x1.3x1.9x12.9x
EV / Sales28.3x7.2x3.8x4.0x16.1x
Gross Profit, Adj.$77.0M$70.4M$56.4M$67.7M$55.2M
YoY %-42.3%-8.6%-20.0%+20.2%-18.5%
Margin %75.6%76.5%62.5%68.8%100.0%
EV / Gross Profit37.5x9.5x6.1x5.8x16.1x
EBITDA, Adj.$-432.0M$-227.2M$-127.4M$-125.5M$-129.7M
YoY %-18.1%+47.4%+43.9%+1.5%-3.4%
Margin %-423.9%-246.8%-141.4%-127.5%-234.9%
EV / EBITDA-6.7x-2.9x-2.7x-3.1x-6.9x
EBIT$-446.1M$-376.2M$-263.7M$-145.6M$-140.1M
YoY %-4.9%+15.7%+29.9%+44.8%+3.8%
Margin %-437.8%-408.6%-292.6%-147.9%-253.7%
EV / EBIT-6.5x-1.8x-1.3x-2.7x-6.3x
Net Income$-523.8M$-368.2M$-276.1M$-119.0M$-164.1M
YoY %-17.9%+29.7%+25.0%+56.9%-37.9%
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (GAAP)-$42.90-$29.55-$21.75-$8.68-$9.73
YoY %-14.9%+31.1%+26.4%+60.1%-12.1%